Ballantyne CM, Entman ML Circulation 2002; 106: High serum concentrations of soluble cellular adhesion molecules have been associated with the development of coronary artery disease, but it is not known if a similar relationship exists between these serum proteins and early-onset peripheral vascular disease. Pradhan et al. addressed this question by studying 14 916 apparently healthy men who had enrolled in the Physicians' Health Study (USA). One hundred and forty of these volunteers developed symptomatic peripheral vascular disease over a 9-year follow-up period. Pradhan et al. measured the serum concentrations of soluble intercellular adhesion molecule-1 and soluble vascular adhesion molecule-1 at the time of enrolment in to the study. Men who developed symptoms were then compared with those who did not. The serum concentration of soluble intercellular adhesion molecule-1 was found to have been higher in symptomatic men, even after adjustment for lipid and non-lipid risk factors. Soluble vascular adhesion molecule-1, however, did not show such a relationship.
High serum concentrations of soluble cellular adhesion molecules have been associated with the development of coronary artery disease, but it is not known if a similar relationship exists between these serum proteins and early-onset peripheral vascular disease. Pradhan et al. addressed this question by studying 14 916 apparently healthy men who had enrolled in the Physicians' Health Study (USA). One hundred and forty of these volunteers developed symptomatic peripheral vascular disease over a 9-year follow-up period. Pradhan et al. measured the serum concentrations of soluble intercellular adhesion molecule-1 and soluble vascular adhesion molecule-1 at the time of enrolment in to the study. Men who developed symptoms were then compared with those who did not. The serum concentration of soluble intercellular adhesion molecule-1 was found to have been higher in symptomatic men, even after adjustment for lipid and non-lipid risk factors. Soluble vascular adhesion molecule-1, however, did not show such a relationship.
Although there is now much evidence to suggest that the serum concentration of soluble intercellular adhesion molecule-1 is associated with the development of atherosclerosis in multiple vascular beds, Ballantyne and Entman have given cause for caution before reaching a conclusion. Thus, too little is known about the cells and tissues of origin of these serum proteins, about how these molecules are generated and catabolized and about the bioactivity of these serum proteins. Ballantyne and Entman advocate large population studies and clinical trials to elucidate these issues. Vasan RS, Benjamin EJ, Larson MG, Leip EP, Wang TJ, Wilson PW et al. JAMA 2002; 288: 1252-9 Left ventricular systolic dysfunction and left ventricular hypertrophy are (treatable) precursors of left ventricular failure. Echocardiography can detect these clinical states and so hopefully lead to treatment before ventricular failure is too advanced. Community-wide screening by echocardiography, however, would cost too much to be viable. Patients with left ventricular systolic dysfunction and left ventricular hypertrophy have high plasma concentrations of plasma natriuretic peptides. Could these relatively inexpensive tests act as a means of screening?
Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: The Framingham Heart Study
Vasan et al. used 3532 subjects (mean age 58 years, 46% men) enrolled in the Framingham O¡spring Study. All underwent a routine physical examination, electrocardiography, echocardiography and had blood samples taken for, amongst other analytes, plasma natriuretic peptides. The percentages of subjects who had hypertension, diabetes mellitus, cardiovascular disease and previous myocardial infarction were about 40%, 10%, 10% and 5%, respectively. Table 3 of Vasan et al. is a complex construct that gives the performance characteristics of the plasma natriuretic peptides in terms of sensitivity, speci¢city, predictive values and likelihood ratios for detecting left ventricular systolic dysfunction and left ventricular hypertrophy. ROC curves were also used to analyse data. Su¤ce to state that Vasan et al. found that the performance of plasma natriuretic peptides in detecting left ventricular systolic dysfunction and left ventricular hypertrophy was`suboptimal'. Thus, the area under the ROC curve for detecting left ventricular systolic dysfunction and left ventricular hypertrophy was only about 0¢75.
Vasan et al. conclude that the low sensitivity of these tests at 95% speci¢city would o¡set any potential usefulness of screening. These tests may have a role when incorporated in a clinical scoring system. The implications of this paper should be considered by all those about to embark on measuring natriuretic peptides.Well worth a read.
(MHC), myoglobin, creatine kinase (CK) and creatine kinase isoenzyme MB (CKMB) in 39 patients with con¢rmed polymyositis (PM) or dermatomyositis (DM) was examined. There were no signi¢cant di¡erences between patients with PM or DM and the two groups were pooled for further analysis. Although no patient had any clinical evidence of myocardial damage (as assessed by ECG, echocardiogram and clinical presentation) CKMB and cTnT were elevated in 51% and 41% of patients, respectively, whereas cTnI was found to be increased in only one patient (2¢5%).
The authors consider that the determination of CKMB as a marker of cardiac damage in patients with myopathies is useless as chronic degeneration and regeneration of skeletal muscle leads to a signi¢cant increase in CKMB. Myoglobin was found to o¡er no signi¢cant advantages over other markers of muscle damage and although the structurally bound protein, MHC did not prove to be a more useful marker of muscle damage than either CK or myoglobin (cytoplasmic markers), the authors suggest that an increase in MHC is clearly indicative of muscle necrosis. Furthermore, as the MHC assay detects both MHC of slow twitch skeletal muscle ¢bres and cardiac MHC, given that the cTnI was undetectable in all but one patient, it was concluded that the MHC had been released from skeletal muscle.
Increased cTnT was found to correlate with the severity of disease and concentrations of CKMB, MHC and myoglobin, suggesting release of cTnT from skeletal muscle. Although cTnT is expressed in small amounts by skeletal muscle during fetal development, it is not expressed by healthy adult skeletal muscle. However, as fetal genes are re-expressed by regenerating muscle, the authors hypothesize that cTnT isoforms could be re-expressed in damaged or regenerating skeletal muscle. The possibility that the increased cTnT is due to sub-clinical cardiac damage missed by imaging techniques is also considered. In contrast, no signi¢cant correlations between cTnI and other muscle markers or severity of disease was found. The authors conclude that cTnI is the most speci¢c marker of cardiac damage in patients with myositis, although cTnT may have a possible prognostic value. Two recent audits of outcome of transsphenoidal surgery for Cushing's disease in UK centres have highlighted some important issues that require standardization if accurate comparisons are to be made. They form the basis of the Commentary published in the same journal.
Ideally, the selective and complete removal of a corticotrophadenoma should cure Cushing's disease and cause no other pituitary dysfunction. The outcome following transsphenoidal surgery for Cushing's disease varies widely between centres and is dependent on the criteria used to de¢ne remission as well as the skills and experience of the surgeon.
Both studies reviewed the outcome of patients in a single centre over a long period (20/30 years). The de¢nition of remission was identical in both studies (i.e. a post-operative serum cortisol concentration of less than 50 nmol/ L in a sample collected 24 h after cessation of steroid cover). In the series reported by Yap et al., the blood samples were collected on the third or fourth post-operative day (no time noted) and at 09.00h within the ¢rst week of surgery in the series reported by Rees et al. The dose of medication was not stated in either study. All patients were operated on by the same surgeon (Yap et al.) or one of three surgeons (Rees et al.) . In both series, di¡erent methods for measuring serum cortisol were used during the study period. These included competitive binding assays, inhouse radioimmunoassay and a number of commercial immunoassay kits.
Similar remission rates were reported by both centres. Clinical and biochemical remission was achieved in 77% (41/45 patients) with only two recurrences (5%) in the series reported by Rees et al. An immediate post operative remission rate of 685% (61/89 patients) was achieved by Yap et al. with seven of these 61 patients experiencing disease recurrence during follow-up. The follow-up period in the former group was a median of 6 years (range 6 months to 6 years) whereas in the latter group it was a mean of 363 months (6^60 months).
Di¤culties in assessing these ¢ndings include the criteria used for disease remission and the sensitivity and speci¢city of the various biochemical tests used for both the initial diagnosis of Cushing's disease as distinct from ectopic ACTH secretion and its subsequent recurrence. In addition, the remission rate quoted by Rees et al. was achieved at the expense of some degree of hypopituitarism.
It is important that the availability of this type of data continues so that understanding of this complex area increases and that outcomes can be further improved.
Ruth Lapworth
William Harvey Hospital Ashford, UK
Special issue -Prolactin and systemic lupus erythematosus: mechanisms and clinical studies
Walker SE, Yu-Lee L-Y (eds) Lupus 2001; 10: Prolactin is a commonly measured pituitary hormone whose usual clinical use is for the management of disorders of the hypothalamic^pituitary^gonadal (HPG) axis in infertility. Less well known is the fact that prolactin is also a cytokine, secreted by immune cells which appears to play an important role in the regulation of the human immune response, including autoimmune diseases. Such interaction is currently of interest to clinical immunologist s and rheumatologists and may in due course become relevant to clinical biochemists. A special issue of Lupus has been dedicated to the interaction between prolactin, the immune system and the autoimmune illness, systemic lupus erythematosus (SLE). Part I deals with the production of prolactin and Part II discusses the mode of action of non-pituitary prolactin. Parts III and IV deal with the e¡ect of prolactin on immune responses and haemopoiesis and the ¢nal part focuses on prolactin and SLE. A total of 14 review articles are included in this special issue.
In serum, prolactin circulates in many isomeric forms as well as aggregates and macroprolactin. Furthermore, prolactin molecules may become glycosylated. The immune cells appear to secrete a wide range of bioactive and immunoreactive forms of prolactin, with MW ranging from 11^60 kDa. Prolactin secreted by the immune cells may have paracrine and endocrine e¡ect, however, it is not clear how much of these forms circulate in serum or their concentrations in health and disease. Because prolactin is measured by immunoassays, di¡erent assays detect in addition to monomeric prolactin other forms such as macroprolactin to a variable extent. Macroprolactin is considered to be biologically inactive, with no pathophysiological role in the function of the HPG axis. However, emerging evidence suggests that macroprolactinaemia could have an attenuated biological activity in the autoimmune disease SLE. Patients with SLE and macroprolactinaemia lack the symptoms of hyperprolactinaemia such as menstrual disturbances and/or galactorrhoea, but appear to show lesser clinical and serological lupus activity. Although such clinical and epidemiological ¢ndings are interesting, research is still in its early stages and further work will be needed before better understanding of the role (if any) of the various isomeric forms of circulating prolactin, and macroprolactin. Particularly since the latter has a prevalence of 51 0% in the population and up to 20^30% of patients with SLE.
